TRANSIENT HIGH-LEVELS OF VIREMIA IN PATIENTS WITH PRIMARY HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 INFECTION
TRANSIENT HIGH-LEVELS OF VIREMIA IN PATIENTS WITH PRIMARY HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 INFECTION
复制标题
DOI：
10.1056/nejm199104043241405
复制
发表时间：
1991-04-04
影响因子：
158.5
通讯作者：
HO, DD
中科院分区：
文献类型：
--
作者：
DAAR, ES;MOUDGIL, T;HO, DD
背景 与人类免疫缺陷病毒1型（HIV-1）的原发性感染的迅速发展的临床图片表明，更好地了解病毒在体内复制的动力学在血清转换前的短时间内可能会提供深入了解获得性免疫缺陷综合征（AIDS）的发病机制。方法和结果。 感染性HIV-1的滴度通过在来自4名原发性感染患者的血浆和外周血单核细胞的连续样本中进行终点稀释培养来确定，峰值滴度为每毫升血浆1000至10，000个组织培养感染剂量和每10（6）个外周血单核细胞100至10，000个感染剂量。 单核细胞中的高病毒负荷通过使用聚合酶链反应方法的定量研究证实。 在短短的10天内，血浆和细胞中的高HIV-1载量在所有四名患者中自发地急剧下降，至少下降了100倍。 虽然p24核心抗原血症和病毒分离先前已被描述在原发性HIV-1感染，本报告文件的大病毒负荷在急性期感染。 病毒载量的迅速和自发下降表明宿主中的有效免疫反应，如果理解的话，可能用于对抗艾滋病。
Background. The rapidly evolving clinical picture of primary infection with the human immunodeficiency virus type 1 (HIV-1) suggests that a better understanding of the kinetics of viral replication in vivo during the short period before seroconversion may provide insight into the pathogenesis of the acquired immunodeficiency syndrome (AIDS).Methods and Results. Titers of infectious HIV-1 were determined by end-point-dilution culture in sequential samples of plasma and peripheral-blood mononuclear cells from four patients with primary infection, with peak titers of 1000 to 10,000 tissue-culture-infective doses per milliliter of plasma and 100 to 10,000 infective doses per 10(6) peripheral-blood mononuclear cells. The high viral burden in mononuclear cells was confirmed by quantitative studies using a polymerase-chain-reaction method. In as little as 10 days, the high HIV-1 load in both plasma and cells decreased spontaneously and precipitously, at least 100-fold, in all four patients.Conclusions. Although p24 core antigenemia and viral isolation have previously been described during primary HIV-1 infection, this report documents the large viral burden during the acute phase of infection. The rapid and spontaneous decline in the viral load suggests an effective immune response in the host that, if understood, may be used to combat AIDS.